Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models

Neuro-Oncology

Volumn 13, Issue 1, 2011, Pages 51-60

  Muldoon, Leslie L ^a,b   Gahramanov, Seymur ^a   Li, Xin ^b   Marshall, Deborah J ^c   Kraemer, Dale F ^b,d   Neuwelt, Edward A ^a,b,e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Ortho Biotech Oncology RandD   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Blood brain barrier; Dynamic susceptibility weighted contrast enhanced magnetic resonance imaging; Intetumumab

Indexed keywords

BEVACIZUMAB; CD51 ANTIGEN; FERUMOXYTOL; INTETUMUMAB; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD FLOW; BRAIN TUMOR; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; DISEASE MODELS, ANIMAL; FEMALE; GADOLINIUM DTPA; HUMANS; INTEGRIN ALPHAV; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, NUDE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79951610184     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq150     Document Type: Article

References (42)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364. (Pubitemid 26272076)
2. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009;6:395-404.
3. Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007;25:4705-4706. (Pubitemid 350086470)
4. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(suppl 3): 11):11-16. (Pubitemid 41680948)
5. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology. 2005;19:7-16.
6. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res. 2005;27:371-377. (Pubitemid 40734696)
7. Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neurooncology. 2008;11:142-150.
8. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab. 2009;29:853-860.
9. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
10. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182-189.
11. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer. 1996;32 A: 2423-2429.
12. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol. 2004;64:207-238. (Pubitemid 39752398)
13. Chen Q, Manning CD, Millar H, et al. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis. 2008;25:139-148.
14. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer. 2004;110:326-335. (Pubitemid 38649882)
15. Mullamitha SA, Ton NC, Parke G J M, et al. Phase I evaluation of a fully human anti av Integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res. 2007;13:2128-2135. (Pubitemid 46649882)
16. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. 2009;30:552-558.
17. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247:490-498.
18. Russell SM, Elliott R, Forshaw D, Golfinos JG, Nelson PK, Kelly PJ. Glioma vascularity correlates with reduced patient survival and increased malignancy. Surg Neurol. 2009;72:242-246.
19. Sadeghi N, D'Haene N, Decaestecker C, et al. Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol. 2008;29:476-482. (Pubitemid 351424060)
20. Gahramanov S, Raslan A, Muldoon LL, et al. Potential for Differentiation of Pseudoprogression from True Tumor Progression with Dynamic Susceptibility-weighted Contrast-enhanced Magnetic Resonance Imaging using Ferumoxytol vs. Gadoteridol: A Pilot Study. J Radiation Oncol Biol Physics. 2010; doi:10.1016/j.ijrobp. 2009.10.072.
21. Weinstein J, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and CNS inflammatory pathologies, a review. J Cereb Blood Flow Metab. 2010;30:15-35.
22. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magnetic Res Imaging. 2007;26:235-249. (Pubitemid 47257720)
23. Veeravagu A, Hou LC, Hsu AR, et al. The temporalcorrelationofdynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Neurol Res. 2008;30:952-959.
24. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21:891-899. (Pubitemid 30262836)
25. Muldoon LL, Manninger S, Pinkston KE, Neuwelt EA. Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery. 2005;57:785-796.
26. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther. 2004;309:594-599. (Pubitemid 38542612)
27. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994-1998. (Pubitemid 29309448)
28. Soltau J, Drevs J. Mode of action and clinical impact of VEGF signaling inhibitors. Expert Rev Anticancer Ther. 2009;9:649-662.
29. Fiorilli P, Partridge D, Staniszewska I, et al. Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation. Lab Invest. 2008;88:1143-1156.
30. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alphav integrins. Science. 1995;270:1500-1502. (Pubitemid 3005294)
31. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alphavbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
32. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha (v) integrin antagonist. Neurosurgery. 2001;48:151-157. (Pubitemid 32039837)
33. Yamada S, Bu X-Y, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery. 2006;59:1304-1312. (Pubitemid 44949775)
34. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610-5617.
35. Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alphavbeta3 and alphavbeta5 integrin receptor antagonist. Cancer Res. 2001;61:2232-2238. (Pubitemid 32692053)
36. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6:3056-3061. (Pubitemid 30637728)
37. Neuwelt EA, Várallyay CG, Manninger S, et al. Potential of ferumoxytol nanoparticle MR imaging, perfusion, and angiography in CNS maliganacy: a pilot study. Neurosurgery. 2007;60:601-611. (Pubitemid 46581060)
38. Batchelor TT, Sorensen AG, Di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95. (Pubitemid 46075199)
39. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res. 2005;11:5827-5832. (Pubitemid 41170309)
40. Li X, Rooney WD, Springer CS, Jr. A unified magnetic resonance imaging pharmacokinetic theory: intravascular and extracellular contrast reagents. Magn Reson Med. 2005;54:1351-1359. (Pubitemid 41740764)
41. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med. 2003;49:848-855. (Pubitemid 36523471)
42. Ferrier MC, Sarin H, Fung SH, et al. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia. 2007;9:546-555. (Pubitemid 47121828)